FINWIRES · TerminalLIVE
FINWIRES

TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial

By

TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.

Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.

Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.

Related Articles

Asia

Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches

Telix Pharmaceuticals (ASX:TLX) shares fell 3% in recent Monday trade after the company said late Friday it has entered into letters of intent to pursue collaborations with EDAP TMS and Profound Medical, developers of minimally invasive and image-guided ablative treatment technologies for prostate cancer.The company said in a statement that the collaborations will explore the investigational use of its prostate-specific membrane antigen positron emission tomography imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound and other image-guided therapies designed to treat localized prostate cancer, including transurethral ultrasound ablation.

ASX:TLX
Asia

ITC Properties Explores AI Infrastructure Venture With Telecom Services Firm; Shares Jump 12%

ITC Properties (HKG:0199) signed a memorandum of understanding with Beijing Qiyuan Zhisuan Data Technology to explore cooperation in artificial intelligence infrastructure and data center businesses, according to a May 15 Hong Kong bourse filing.Shares of the property developer rose nearly 12% in late-morning trade on Monday.The companies plan to collaborate on AI infrastructure, internet data center resources, artificial intelligence data center development, computing power services, and data center operations.ITC said the parties may also explore a variable interest entity structure involving Qiyuan Zhisuan, which holds telecommunications licenses in China for internet data center and internet access services.The memorandum will remain valid for 12 months unless terminated earlier.

HKG:0199
Asia

ChinHung International Wins KRW62.6 Billion Housing Redevelopment Project in Jeongneung-dong, South Korea

ChinHung International (KRX:002780) secured a construction order to build 209 apartment units and ancillary welfare facilities at the site around 223-1 Jeongneung-dong, Seongbuk-gu, Seoul, according to a Monday filing on the Hong Kong Stock Exchange.The contract is valued at 62.6 billion won. The contract period runs until the end of the month, marking 32 months from the actual start of construction, the filing said.Shares of ChinHung International fell nearly 1% in recent trade.

KRX:002780